Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events

Medicilon Events

Hot information:
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division| Medicilon FTE services & FFS services - flexible and efficient cooperation model| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon
Mar 03,2023
Medicilon assists Carephar first potassium-ion-competitive acid blocker "Carenoprazan Tablets" approved for sales in China
The Class 1 new drug Carenoprazan Hydrochloride Tablets, for the treatment of duodenal ulcer and reflux esophagitis, independently developed by Jiangsu Carephar was officially approved for sales in market. Medicilon has provided research and development from compound design to preclinical candidate compounds, as well as most of the in vitro H+K+-ATPase testing and other services and the Carenoprazan has been successfully approved.
More
Medicilon assists Carephar first potassium-ion-competitive acid blocker "Carenoprazan Tablets" approved for sales in China
Feb 24,2023
Medicilon Assists CGeneTech's Oral Hypoglycemic DPP-4 Inhibitor, New Drug Application (NDA) Accepted
CGeneTech submitted the DPP-4 inhibitor, for the treatment of type 2 diabetes, to the NMPA for approval. Medicilon, as a partner of CGeneTech, provided comprehensive preclinical research services in compliance with GLP regulations, including pharmacodynamic research, pharmacokinetic research and safety evaluation, as well as Phase I clinical bioanalysis to facilitate its efficient and high-quality R&D.
More
Medicilon Assists CGeneTech's Oral Hypoglycemic DPP-4 Inhibitor, New Drug Application (NDA) Accepted
Feb 17,2023
Medicilon Helps iMBioRay's CAR-raNK Cell Therapy Approved Clinical Trial
Recently, IBR854 Cell Injection of iMBioRay (Hangzhou) Biomedical Co., Ltd. (iMBioRay) obtained the permission of the NMPA for clinical trials. Shanghai Medicilon Inc. (Medicilon), as a partner of IBR854 Cell Injection, provides efficient, high-quality and comprehensive preclinical research services (including pharmacokinetic studies and safety evaluation) in compliance with GLP regulations. The IBR854 Cell Injection is successfully approved at the end.
More
Medicilon Helps iMBioRay's CAR-raNK Cell Therapy Approved Clinical Trial
Feb 03,2023
Medicilon 19th Anniversary
Medicilon welcome the year of 2023 and also welcome the 20th year of success. 19 years of overcoming obstacles, 19 years of non-stop innovation and 19 years of R&D acceleration, Medicilon, as a professional biopharmaceutical preclinical comprehensive R&D service CRO, covers the entire process of preclinical new drug research such as drug discovery, pharmaceutical research and preclinical research, in addition of expanding the CDMO service and the global development.
More
Medicilon 19th Anniversary
Jan 06,2023
Medicilon Cell & Gene Therapy Drug R&D Service Platform
Medicilon's preclinical research services cover pharmacodynamic research, drug safety evaluation, pharmacokinetic research, bioanalysis, etc. The establishment of a complete gene therapy R&D platform can provide one-stop services for research on pharmacological efficacy, biodistribution and safety evaluation of cell and gene therapy products.
More
Medicilon Cell & Gene Therapy Drug R&D Service Platform
Jan 06,2023
2022 Memories | Medicilon Is For You
Looking back at Medicilon 2022, even the most extraordinary days never stop moving forward. Because there is always light guiding us to move forward; there is always love, shining for a long time. Thank you for the moments and memories that link us together. This accumulates as the strength to forge ahead in the New Year.
More
2022 Memories | Medicilon Is For You
Dec 28,2022
Medicilon participated in the annual meeting of the American Chinese Biomedical Technology Association on Christmas Eve
The 27th Annual Chinese Biopharmaceutical Association (CBA) Meeting will be held on December 17, 2022, at the Marriott Washingtonian Center in Maryland!
More
Medicilon participated in the annual meeting of the American Chinese Biomedical Technology Association on Christmas Eve
Dec 28,2022
Listed for 3 consecutive years! Medicilon won the "Top 20 Chinese R&D CRO Enterprises in 2022"
Shanghai Medicilon Inc. (Medicilon), as a one-stop pharmaceutical preclinical R&D service platform in China, was once again selected as one of the "Top 20 Chinese R&D CRO Enterprises in 2022" by virtue of its solid R&D strength. This is the 3rd consecutive year that Medicilon has won this honorary title!
More
Listed for 3 consecutive years! Medicilon won the "Top 20 Chinese R&D CRO Enterprises in 2022"
Dec 28,2022
Translational Medicine - Accelerate the R&D process of innovative drugs and precision medicine
The Medicilon translational medicine platform has an experienced professional technical team, starting from the mechanism of action of drug targets and the clinical application of biomarkers, based on the discovery and validation of biomarkers, combining a variety of different technology platforms and state-of-art instruments, and creating multiple bioanalytical methods, to reduce the cost and time of drug R&D, and provide diverse and efficient services for different types of drugs, different kinds of pharmaceutical companies and projects at different R&D stages.
More
Translational Medicine - Accelerate the R&D process of innovative drugs and precision medicine
Dec 22,2022
Medicilon wish you a merry christmas
Christmas is coming up! Wishing you all the Hope, Wonder, and Joy! Have a delicious time!
More
Medicilon wish you a merry christmas
Dec 09,2022
Holiday Promotion: Medicilon Antibody Development Technology Service with Discount Price
Medicilon Antibody Development Technical Service is here to help you develop new drugs with high cost performance, high efficiency and high quality.
More
Holiday Promotion: Medicilon Antibody Development Technology Service with Discount Price
Dec 09,2022
Congratulation to the Expansion of Medicilon Drug Research and Development Laboratory
On December 4th, with the completion of the last concrete pouring, the expansion project of the drug research and development laboratory of Shanghai Medicilon Inc has been completed. This marks the further strengthening of Medicilon's one-stop biopharmacetical preclinical R&D service platform capabilities.
More
Congratulation to the Expansion of Medicilon Drug Research and Development Laboratory